info_outline
Ep. 2: Antegrade Administration with Dr. Jennifer Linehan
10/23/2024
Ep. 2: Antegrade Administration with Dr. Jennifer Linehan
In this episode of The UroGist, host Dr. Mike Louie of UroGen sits down with guest Dr. Jennifer Linehan, an Associate Professor of Urologic Oncology and Section Head of Urology Translational Research at the St. John's Cancer Institute in Santa Monica, CA to discuss the nuances of antegrade administration of an innovative treatment for low-grade upper tract urothelial cancer. While discussing the OLYMPUS study, the episode refers to 84% durability for 12 months for patients with low-grade upper tract urothelial cancer, which was found in interim data. The final durability of response data from the OLYMPUS trial for all 41 patients was 82% at 12 months. · · · · · · · · Lerner, Seth. Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): a prospective single-arm phase 3 trial. The Lancet Oncology, 2020 Matin SF, Pierorazio PM, Kleinmann N, Gore JL, Shabsigh A, Hu B, Chamie K, Godoy G, Hubosky SG, Rivera M, O'Donnell M, Quek M, Raman JD, Knoedler JJ, Scherr D, Weight C, Weizer A, Woods M, Kaimakliotis H, Smith AB, Linehan J, Coleman J, Humphreys MR, Pak R, Lifshitz D, Verni M, Klein I, Konorty M, Strauss-Ayali D, Hakim G, Seltzer E, Schoenberg M, Lerner SP. Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final Report. J Urol. 2022 Apr;207(4):779-788. doi: 10.1097/JU.0000000000002350. Epub 2021 Dec 17. PMID: 34915741.
/episode/index/show/84eebaee-ab85-4777-a7b8-4fd2943e44b0/id/33516817
